Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?

This article was originally published in RPM Report

Executive Summary

The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.


Related Content

Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
Regulatory Innovation: A Dialogue (Part II)
The Real Obesity Drugs Hurdle: Paying for Them
Weighing the Risks: Vivus View of Regulatory Risks in Qnexa Reprise
FDA and the R&D Crisis: Time to Stop the Blame Game
Just a Minute: The Final Step in Advisory Committee Process
Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance
A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them
Weighing the Regulatory Climate: Qnexa and the New Approval Model
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts